Vaccine development for COVID-19
Held on: 28 October 2020
This final webinar in the series will discuss COVID-19 vaccination development and the complexity of global immunisation.
PLEASE NOTE: To receive CPD points this webinar must be viewed via the Praxhub website here.
Watch a recording of the webinar here:
John Litt MBBS, MSC, DRACOG, FRACGP, FAFPHM, PhD, is Associate Professor of General Practice in the Discipline of General Practice, Flinders Prevention, Promotion and Primary Health Care, School of Medicine, Flinders University, Adelaide, South Australia.
An Infectious Diseases Physician and Microbiologist, Dr Paul Griffin was appointed as the Director of Infectious Diseases at Mater Health Services in 2013. In addition Dr Griffin continues appointments as Principal Investigator at Q-Pharm, as Visiting Scientist/Honorary Research Fellow at Mater Medical Research Institute and Queensland Institute of Medical Research, and also as Senior Lecturer at the University of Queensland. Dr Paul Griffin’s primary research interests include clinical trials in the field of infectious diseases particularly malaria human challenge and transmission blocking studies, as well as the detection of antibiotic resistance particularly VRE by mass spectrometry in the clinical microbiology laboratory.
Gary Grohmann is a virologist and a former Director of Immunobiology (a WHO Essential Regulatory Laboratory) at the Therapeutic Goods Administration (TGA) in Australia (1997- 2015), responsible for vaccine testing and registration. During this time he also represented the TGA on various WHO committees involving influenza issues. He then undertook a number of engagements with WHO (2015-2018) in Geneva with the Health Systems and Innovation Group (working with the Technology Transfer Initiative assisting developing vaccine manufacturers and the WHO Research blueprint), the Global Action Plan (GAP) for Influenza Vaccines, the Essential Medicines Programme (Reviewing Biocontainment); the Global Influenza Programme (Vaccine strain selection committee and the “Switch” meetings); and the Pandemic Influenza Preparedness Framework Review Group Secretariat (lead).
By the end of this presentation, attendees will be able to:
1. Describe the evaluation cycle eg. Phase I to Phase III trials
2. Explain the nature of immunity to COVID-19, including antibody, T cells and adjuvants, and recognise the markers of immunity and factors that influence effectiveness eg immunosenescence, patient age, and other co-morbidities
3. Describe the issues (ethical and otherwise) involved in selecting who to vaccinate with a COVID-19 vaccine eg. HCW, elderly or others deemed to be “at risk”
4. Recognise the importance of obtaining global immunity to COVID-19 through universal vaccination, and explain the factors that are likely to both facilitate and inhibit vaccination against COVID
5. Recognise the need to accurately record and update the AIR once a patient has received the COVID-19 vaccine